BI-3802是一種高效的 BCL6 降解劑，通過抑制 BCL6 的 BTB 結構域，IC50 小于或等于 3 nM；BI-3802 具有抗腫瘤活性。

ARV-393是一種口服有效的?PROTAC，可利用泛素蛋白酶體系統(tǒng)、靶向降解?BCL6。ARV-393 由分別靶向?BCL6?和 E3 連接酶?cereblon?的配體耦連組成。

BI-3812是一種 BCL6 抑制劑，通過抑制 BCL6 的 BTB 結構域，IC50 小于或等于 3 nM。

Glycochenodeoxycholic acid是肝臟中由甘氨鵝脫氧膽酸和甘氨酸產(chǎn)生的一種相對有毒的膽鹽。Glycochenodeoxycholic acid 通過抑制人正常肝細胞中溶酶體蛋白水解和增加溶酶體 pH 來抑制自噬體 (Autophagosome) 形成和損害溶酶體功能，導致人肝細胞凋亡 (Apoptosis)。Glycochenodeoxycholic acid 通過激活?STAT3?信號通路誘導肝癌細胞的干細胞性質和化療耐藥性。

TL4-12是一種選擇性MAP4K2/GCK抑制劑，能下調IKZF1和BCL-6，抑制MM細胞增殖（IC50=37 nM），并誘導凋亡。TL4-12可用于克服多發(fā)性骨髓瘤（MM）中的免疫調節(jié)藥物耐藥性。

CID5721353是一種B細胞淋巴瘤6（BCL6）抑制劑。

FX1 is a BCL6 inhibitor that effectively blocks BCL6 N-terminal BTB domain-mediated corepressors chromosome recruitment (by 61-87%/SMRT and 67-82%/BCOR; 50 μM FX1 for 30 min) and selectively suppresses BCL6-depenent growth (GI50 16-54 μM; >125 μM against BCL6-independent cells) in diffuse large B cell lymphoma (DLBCL) cultures, exhibiting greater affinity than its structure analog 79-6 or BCL6 corepressor SMRT for BTB domain (KD = 7 μM/FX1, 30 μM/SMRT, 129 μM/79-6). FX1 shows greater efficacy than 79-6 in reversing BCL6/corepressors-mediated target genes repression in vitro (IC50 = 35 μM vs. 318 μM with 79-6 by HEK293T-based reporter assay) and in suppressing OCI-Ly7 DLBCL xenograft tumor growth mice in vivo (100% vs. 45% suppression with respective compound via 25 mg/kg/day i.p.).

Glycochenodeoxycholic acid is a bile salt formed in the liver from chenodeoxycholic acid and glycine, usually found as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed.

BCL6-IN-7 is a potent BCL6 protein-protein interaction inhibitor with Kd of 78 nM.